European Journal of Cancer
Volume 46, Issue 1 , Pages 21-32, January 2010

Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics☆

  • Jean-Louis Steimer

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Svein G. Dahl

      Affiliations

    • Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway
    • ,
  • Dinesh P. De Alwis

      Affiliations

    • Eli Lilly & Company, Surrey, UK
    • ,
  • Ursula Gundert-Remy

      Affiliations

    • Bundesinstitut für Risikobewertung, Berlin, Germany
    • ,
  • Mats O. Karlsson

      Affiliations

    • Uppsala University, Uppsala, Sweden
    • ,
  • Jirina Martinkova

      Affiliations

    • Charles University of Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
    • ,
  • Leon Aarons

      Affiliations

    • University of Manchester, Manchester, United Kingdom
    • Corresponding Author InformationCorresponding author: Address: University of Manchester, School of Pharmacy and Pharmaceutical Sciences, Oxford Road, M13 9PL Manchester, United Kingdom. Tel.: +44 161 275 2357; fax: +44 161 275 2396.
    • ,
  • Hans-Jürgen Ahr

      Affiliations

    • Bayer Health Care, Leverkusen, Germany
    • ,
  • Jean Clairambault

      Affiliations

    • INRIA, Paris, France
    • ,
  • Gilles Freyer

      Affiliations

    • Medical Oncology Unit, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
    • ,
  • Lena E. Friberg

      Affiliations

    • Uppsala University, Uppsala, Sweden
    • ,
  • Steven E. Kern

      Affiliations

    • College of Pharmacy, University of Utah, USA
    • ,
  • Annette Kopp-Schneider

      Affiliations

    • Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
    • ,
  • Wolf-Dieter Ludwig

      Affiliations

    • Robert-Rössle-Klinik Oncology and Tumorimmunology, Berlin-Buch, Germany
    • ,
  • Giuseppe De Nicolao

      Affiliations

    • Department of Computer Engineering and Systems Science, University of Pavia, Pavia, Italy
    • ,
  • Maurizio Rocchetti

      Affiliations

    • Accelera, Milan, Italy
    • ,
  • Iñaki F. Troconiz

      Affiliations

    • Departamento de Farmacia y Tecnología Farmacéutica, University Navarra, Pamplona, Spain

Received 16 April 2009; received in revised form 30 September 2009; accepted 9 October 2009. published online 02 December 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This paper is based in part on discussions at a COST B25 expert meeting held in Prague, Czech Republic, on 20–21st September 2007. Participating experts were Leon Aarons (UK), Hans-Jürgen Ahr (Germany), Jean Clairambault (France), Svein G. Dahl (Norway), Dinesh De Alwis (UK), Gilles Freyer (France), Lena Friberg (Sweden), Ursula Gundert Remy (Germany), Steve Kern (US), Anette Kopp-Schneider (Germany), Wolf-Dieter Ludwig (Germany), Jirina Martinkova (Czech Republic), Maurizio Rocchetti (Italy), Giuseppe De Nicolao (Italy), Jean-Louis Steimer (Switzerland), Iñaki F. Troconiz (Spain).

PII: S0959-8049(09)00758-8

doi:10.1016/j.ejca.2009.10.011

European Journal of Cancer
Volume 46, Issue 1 , Pages 21-32, January 2010

Article Tools

* Image Usage & Resolution